Navigation Links
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Date:12/2/2010

with advanced HIV infection.

NEUPOGEN is contraindicated in patients with hypersensitivity to filgrastim or excipients. Not to be used for escalation of cytotoxic chemotherapy doses above established regimens or administered to patients with severe congenital neutropenia (Kostman's Syndrome) with abnormal cytogenetics.

Administer NEUPOGEN with caution in secondary AML. Safety and efficacy of NEUPOGEN not established in de novo AML patients < 55 years with good cytogenetics (t(8;21), t(15;17) and inv(16)). The onset of pulmonary signs (cough, fever, dyspnoea) in association with radiological signs of pulmonary infiltrates and deterioration in pulmonary function may be preliminary signs of Acute Respiratory Distress Syndrome (ARDS). Discontinue NEUPOGEN and give appropriate treatment.

Other adverse events of special importance associated with NEUPOGEN include GvHD and fatalities in patients receiving G-CSF after allogeneic bone marrow transplantation, very rare cases of splenic rupture reported in healthy donors and patients, and hypersensitivity-type reactions in cancer patients. NEUPOGEN should be permanently discontinued in patients who experience a serious allergic reaction. NEUPOGEN is not recommended in period 24 hours before to 24 hours after chemotherapy.  Neulasta is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Neulasta is contraindicated in patients with hypersensitivity to pegfilgrastim or excipients.

Neulasta should not be used in patients with MDS, CML and secondary AML. The safety and efficacy of Neulasta administration in de novo AML patients aged < 55 years with cytogenetics t(15;17) have not been established.

Neulasta should be discontinued following preliminary signs of
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
2. Choices
3. Empowerment Competition
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
6. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
7. Amgen Announces Webcast of 2010 Third Quarter Financial Results
8. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
9. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
10. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
11. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... , Sep. 04, 2015 ... addition of the "Stability Testing of Pharmaceuticals (London, ... offering. By attending this comprehensive two day ... design efficient stability studies that are suitable for global ... stability studies and manage stability samples and facilities ...
(Date:9/3/2015)... , Sept. 3, 2015 ... Potentials of New Drugs, Industry Changes and Emerging ... the human ovaries? Visiongain,s new study forecasts those ... growth in that industry. You also explore trends, ... Our report gives revenue predictions to 2025 ...
(Date:9/3/2015)... 2015 About self-monitoring blood glucose device ... electronic device. It consists of a glucose sensor ... levels through radiowaves from the sensor to a ... of self-monitoring blood glucose devices can improve self-management ... proper diabetes treatment. Technavio,s analysts forecast ...
Breaking Medicine Technology:Stability Testing of Pharmaceuticals: 2 Day Seminar - London, UK - December 2-3, 2015 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 2Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 3Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 4Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 5Ovarian Cancer Drug Therapy: Companies, R&D and Revenue Forecasts 2015-2025: Recently Approved Treatments Give High Market Potential 6Global Self-monitoring Blood Glucose Devices Market 2015-2019 2
... achieve undetectable viral load in Phase,IIa trial within ... care, SAN FRANCISCO, Nov. 1 New ... protease inhibitor (PI) being,developed by Tibotec BVBA for ... Tibotec will present findings from three TMC435 studies,including ...
... Higher Sustained Virological Response Rates Recognized as Marker ... 1 A new,independently-conducted study being presented at ... the Study of Liver Diseases (AASLD) shows that,PEGASYS(R) ... response (SVR) rates for hepatitis C patients as,compared ...
Cached Medicine Technology:Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 2Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 3Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 4Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 2New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 3New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 4New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 5New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 6New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients 7
(Date:9/4/2015)... Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... material has been developed that changes color when subjected to an impact force that ... notes, could be implemented in helmets or other sporting equipment so that coaches or ...
(Date:9/4/2015)... San Diego, California (PRWEB) , ... September 04, 2015 , ... ... affiliates on behalf of Tanya De La Paz. , Schmidt National Law Group, ... for the Northern District of California against Bayer Corp., Bayer Essure, Inc., and other ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced today that ... of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain Committees. , ... the consumer goods industry, it can be difficult for companies to navigate, stay ...
(Date:9/4/2015)... ... ... “Getting away from the daily stressors and distractions of life may be ... says Jean Claude Wietzel, general manager at Four Seasons Resort Maui at Wailea. ... Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, has announced ...
(Date:9/4/2015)... ME (PRWEB) , ... September 04, 2015 , ... ... focus on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at ... , Speakers at the 2015 symposium are doctors and researchers at the top ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... /CTL/ -- CareToLive, a not for,profit corporation, received a ... its fight against the FDA on behalf of terminal ... an,appeal in the 6th Circuit Court in Ohio., ... outside of,their grasp," said CareToLive spokesperson, Melody Davis. "Congress ...
... N.J., Nov. 26 Quest Diagnostics,Incorporated (NYSE: ... information and services, announced that it is scheduled ... Conference at the Merrill,Lynch Headquarters in New York ... presentation is scheduled to begin at 10:15 a.m. ...
... are not the best for them, study says , , ... third of prostate cancer patients may receive treatments that ... with urinary, bowel or sexual function, a new study ... give enough information to their doctor or because their ...
... NASDAQ: CRME TSX: COM, VANCOUVER, Nov. 26 /PRNewswire-FirstCall/ ... announced updated guidance for expected,interim results from its Phase ... to complete and disclose the interim,analysis in the fourth ... disclose the interim analysis in March 2008, with the ...
... (p. 30). Senior Writer Suzanne Smalley looks at,GOP presidential ... code, which is at once rigid (in public) and ... adult personality,can be traced back to his childhood and ... family of cops and hoods and to a Catholic ...
... dental care can even start in the womb, experts say ... of Americans is improving as people take better care of ... of the country,s most vulnerable individuals -- children. , Studies ... One federal report found that decay in baby teeth among ...
Cached Medicine News:Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 2Health News:CareToLive Reports: The FDA Fiddles While 30,000 Men Burn 3Health News:Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 2Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 3Health News:Prostate Cancer Treatments Often Compound Existing Health Problems 4Health News:Cardiome Updates Guidance 2Health News:Cardiome Updates Guidance 3Health News:Cardiome Updates Guidance 4Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 2Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 3Health News:NEWSWEEK: Media Lead Sheet/December 3, 2007 Issue (on newsstands Monday, November 26). 4Health News:Tooth Decay Is Kids' Stuff 2Health News:Tooth Decay Is Kids' Stuff 3
Mayfield radiolucent skull clamp....
Endoscopes...
... Storz borescopes are rigid endoscopes for general applications ... system. The diameters of borescopes, i.e. rigid endoscopes, ... viewing directions from 0 up to a 120 ... lens and wide angle view. Endoscopes with working ...
Short system ventriculoscope for free hand use....
Medicine Products: